William Craig, M.D., Professor of Medicine, University of Wisconsin Medical School
Dr. Craig has expertise in bacterial pathogens, in vivo models for bacterial infections and predicting the dose/blood level/efficacy relations for clinical studies from animal models. He is professor of medicine and therapeutics and clinical pharmacology section head, Infectious Diseases at the University of Wisconsin Medical School. He also served on the FDA advisory panel for infectious diseases.

Samuel Danishefsky, Ph.D., Professor & Director Bioorganic Chemistry, Columbia University and Kettering Chair, Sloan-Kettering Institute for Cancer Research
With a 40-year career in the synthetic chemistry of natural products, Dr. Danishefsky has become the recognized international authority on the total synthesis of complex natural products. Dr. Danishefsky's primary research interest is the development of new therapeutic agents from natural products. He is currently a professor at Columbia University and director of its Laboratory for Bioorganic Chemistry, as well as the Kettering Chair at the Sloan-Kettering Institute for Cancer Research in New York.

Arnold L. Demain, Ph.D., Fellow, Drew University
Dr. Demain, fellow at Drew University, was previously head of fermentation biology, Merck Research Labs and professor of industrial microbiology at MIT. He is a member of the National Academy of Sciences, USA and is one of the founders and a leading international researcher in the discipline of industrial microbiology. He is the recipient of numerous international awards and honors, including 4 honorary doctorates and has more than 400 publications, 10 books and 17 U.S. patents to his credit.

William H. Fenical, Ph.D., Scientific Co-Founder
Dr. Fenical, is professor of oceanography and director of the Center for Marine Biotechnology and Biomedicine at Scripps Institute of Oceanography, University of California, San Diego. Dr. Fenical's research, which has led to more than 300 publications, has focused upon the novel chemicals found in marine life and how these substances might be applied in medical research. More recently, Dr. Fenical's research has demonstrated that the enormous diversity of marine microorganisms found in the world's oceans is a unique resource for drug discovery.

Stephen J. Giovannoni, Ph.D., Professor of Microbiology, Oregon State University
Dr. Giovannoni, professor of microbiology at Oregon State University, is an internationally recognized expert in marine microbiology, genomics and molecular ecology. He is a fellow of the American Academy of Microbiology and editor of numerous prestigious journals. His laboratory studies the distribution, diversity and culture conditions for selected marine bacteria.

Lyle L. Moldawer, Ph.D., Professor of Surgery, University of Florida
Dr. Moldawer is professor of surgery at the University of Florida College of Medicine. As a prominent investigator, he is defining the role that dysregulation between proinflammatory cytokine and cytokine inhibitor production plays in the pathologic host response to acute and chronic inflammatory processes. His laboratory is a leading site for the pharmacology studies of new cytokine-related drugs in vitro and in vivo.

Charles G. Smith, Ph.D., Consultant to the Pharmaceutical Industry
Having held senior research and development positions with a number of pharmaceutical companies, including president of Squibb Institute for Medical Research and vice president research and development of Revlon Health Care Group, Dr. Smith was directly involved or administratively responsible for research and development programs that have led to the marketing of approximately 20 major products. Dr. Smith was also a founder of Vanguard Medica Ltd., a public biotechnology company in the United Kingdom.

Daniel Von Hoff, M.D., Professor of Medicine, Molecular and Cellular Biology and Pathology, and Director of the Arizona Cancer Center, University of Arizona in Tucson
Dr. Von Hoff's major interest is in the development of new anticancer agents at the preclinical and clinical level. He is concentrating on the development of molecularly targeted therapies and the discovery of new targets in pancreatic cancer. Dr. Von Hoff has published more than 480 papers, 122 book chapters and more than 820 abstracts. He is the past president of the American Association for Cancer Research, a fellow of the American College of Physicians and past board member of the American Society for Clinical Oncology.